Hepatitis C treatment eligibility in an urban population with and without HIV coinfection.
AIDS Patient Care STDS
; 18(4): 239-45, 2004 Apr.
Article
en En
| MEDLINE
| ID: mdl-15142354
ABSTRACT
In an urban referral clinic, 182 hepatitis C-infected adults including 110 (60%) with HIV coinfection were evaluated for pegylated interferon and ribavirin therapy. Overall, only 33% were eligible for treatment. Considering all patients together, the major barriers to treatment were nonadherence with the evaluation process (23%), refusal of treatment (10%), active substance abuse (9%), and medical contraindication (8%). There was a trend toward a higher rate of treatment eligibility in HIV coinfected patients (39% vs. 25%; p = 0.07), who were significantly more likely to be adherent with the evaluation process compared to those with hepatitis C alone (86% vs. 63%; p = <0.001). Acceptance of antiviral therapy for hepatitis C was similar between eligible persons with and without HIV. These findings highlight the need to develop interventions to improve adherence and to manage substance abuse and other comorbidities in order to maximize the impact of interferon and ribavirin therapy on urban patients with hepatitis C.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Polietilenglicoles
/
Ribavirina
/
Infecciones por VIH
/
Interferón-alfa
/
Hepatitis C
/
Selección de Paciente
/
Servicios Urbanos de Salud
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
País/Región como asunto:
America do norte
Idioma:
En
Revista:
AIDS Patient Care STDS
Asunto de la revista:
DOENCAS SEXUALMENTE TRANSMISSIVEIS
/
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Año:
2004
Tipo del documento:
Article